Search This Blog

Friday, April 26, 2013

Oral Anti-Cancer Therapy REVLIMID® Receives Positive CHMP Opinion as Treatment for Patients with Form of Rare Blood Cancer Deletion 5Q Myelodysplastic Syndromes | Celgene Newsroom

Oral Anti-Cancer Therapy REVLIMID® Receives Positive CHMP Opinion as Treatment for Patients with Form of Rare Blood Cancer Deletion 5Q Myelodysplastic Syndromes | Celgene Newsroom

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.